Intra-Cellular Therapies (NASDAQ:ITCI) Price Target Raised to $100.00 at Mizuho

Intra-Cellular Therapies (NASDAQ:ITCIFree Report) had its target price increased by Mizuho from $96.00 to $100.00 in a research note released on Friday, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

Several other analysts have also issued reports on ITCI. Robert W. Baird lifted their target price on shares of Intra-Cellular Therapies from $83.00 to $103.00 and gave the company an outperform rating in a research report on Wednesday, April 17th. Canaccord Genuity Group boosted their price objective on Intra-Cellular Therapies from $107.00 to $113.00 and gave the stock a buy rating in a research note on Thursday. The Goldman Sachs Group increased their target price on Intra-Cellular Therapies from $67.00 to $77.00 and gave the company a neutral rating in a report on Wednesday, April 17th. Royal Bank of Canada reiterated an outperform rating and set a $86.00 price target on shares of Intra-Cellular Therapies in a research report on Wednesday, April 3rd. Finally, Cantor Fitzgerald restated an overweight rating and issued a $120.00 price objective on shares of Intra-Cellular Therapies in a report on Friday, June 14th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of Moderate Buy and a consensus price target of $92.67.

Check Out Our Latest Stock Report on Intra-Cellular Therapies

Intra-Cellular Therapies Trading Up 1.4 %

Shares of ITCI stock opened at $76.58 on Friday. Intra-Cellular Therapies has a 12-month low of $45.50 and a 12-month high of $84.89. The business’s 50 day moving average is $69.53 and its two-hundred day moving average is $68.75. The company has a market capitalization of $8.08 billion, a P/E ratio of -66.02 and a beta of 0.97.

Intra-Cellular Therapies (NASDAQ:ITCIGet Free Report) last announced its earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.15. Intra-Cellular Therapies had a negative return on equity of 18.49% and a negative net margin of 21.57%. The firm had revenue of $144.90 million for the quarter, compared to analyst estimates of $141.41 million. During the same quarter last year, the firm posted ($0.46) EPS. The business’s revenue was up 52.0% on a year-over-year basis. On average, research analysts predict that Intra-Cellular Therapies will post -0.51 earnings per share for the current fiscal year.

Institutional Trading of Intra-Cellular Therapies

Large investors have recently added to or reduced their stakes in the stock. Perceptive Advisors LLC acquired a new position in shares of Intra-Cellular Therapies during the 4th quarter valued at about $7,735,000. Quantum Private Wealth LLC boosted its holdings in Intra-Cellular Therapies by 64.7% in the 4th quarter. Quantum Private Wealth LLC now owns 23,705 shares of the biopharmaceutical company’s stock valued at $1,698,000 after purchasing an additional 9,308 shares during the last quarter. Schroder Investment Management Group grew its stake in shares of Intra-Cellular Therapies by 36.7% in the 4th quarter. Schroder Investment Management Group now owns 779,823 shares of the biopharmaceutical company’s stock valued at $55,851,000 after buying an additional 209,331 shares during the period. HealthInvest Partners AB acquired a new stake in shares of Intra-Cellular Therapies during the 4th quarter worth approximately $877,000. Finally, Lighthouse Investment Partners LLC purchased a new stake in shares of Intra-Cellular Therapies during the 4th quarter valued at approximately $4,473,000. 92.33% of the stock is currently owned by hedge funds and other institutional investors.

About Intra-Cellular Therapies

(Get Free Report)

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.

Featured Stories

Analyst Recommendations for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.